Birchview Capital, LP Stoke Therapeutics, Inc. Transaction History
Birchview Capital, LP
- $111 Million
- Q1 2025
A detailed history of Birchview Capital, LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 210,005 shares of STOK stock, worth $2.75 Million. This represents 1.26% of its overall portfolio holdings.
Number of Shares
210,005
Previous 210,000
-0.0%
Holding current value
$2.75 Million
Previous $2.32 Million
39.72%
% of portfolio
1.26%
Previous 1.98%
Shares
7 transactions
Others Institutions Holding STOK
# of Institutions
137Shares Held
56.5MCall Options Held
5.6KPut Options Held
142K-
Black Rock Inc. New York, NY5.41MShares$70.9 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.29MShares$69.3 Million13.01% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$67.1 Million0.56% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$60.7 Million0.37% of portfolio
-
Redmile Group, LLC San Francisco, CA4.49MShares$58.8 Million3.13% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $516M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...